THRD Stock Price, Third Harmonic Bio Inc Quote, Chart

Market Summary

USD11.28+0.13

Delayedas of 30 Apr 2024, 12:20 pm

1.17%

THRD Alerts

1 major insider sales recently.

THRD Stock Price

View Fullscreen

THRD RSI Chart

THRD Valuation

Market Cap

454.0M

Price/Earnings (Trailing)

-14.73

Price/Free Cashflow

-22.04

THRD Price/Earnings (Trailing)

THRD Profitability

Return on Equity

-11.46%

Return on Assets

-11.1%

Free Cashflow Yield

-4.54%

THRD Fundamentals

THRD Earnings

Earnings (TTM)

-30.8M

Earnings Growth (Yr)

40.5%

Earnings Growth (Qtr)

6.9%

Breaking Down THRD Revenue

52 Week Range

11.29

(Low)(High)

Last 7 days

-4.3%

Last 30 days

18.1%

Last 90 days

27.1%

How does THRD drawdown profile look like?

THRD Financial Health

Current Ratio

50.29

THRD Investor Care

Shares Dilution (1Y)

3.23%

Diluted EPS (TTM)

0.78

Tracking the Latest Insider Buys and Sells of Third Harmonic Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	holles natalie c.	sold	-165,214	12.1857	-13,558	ceo
Apr 11, 2024	holles natalie c.	acquired	56,943	4.2	13,558	ceo
Apr 04, 2024	person julie	sold	-11,070	10.00	-1,107	chief administrative officer
Apr 04, 2024	person julie	acquired	4,649	4.2	1,107	chief administrative officer
Dec 05, 2023	conner edward r.	sold	-48,062	10.0339	-4,790	chief medical officer
Dec 05, 2023	conner edward r.	acquired	20,118	4.2	4,790	chief medical officer
Dec 05, 2023	person julie	acquired	54,024	4.2	12,863	chief administrative officer
Dec 05, 2023	person julie	sold	-132,484	10.2996	-12,863	chief administrative officer
Dec 20, 2022	bvf partners l p/il	bought	879,499	4.1086	214,063	-
Sep 19, 2022	orbimed advisors llc	bought	5,100,000	17.00	300,000	-

Which funds bought or sold THRD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.48	-117,455	511,894	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	new	-	15,132	15,132	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-72.31	-20,000	6,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	53,146	127,296	-%
Apr 17, 2024	Annapolis Financial Services, LLC	sold off	-100	-54,850	-	-%
Apr 05, 2024	GAMMA Investing LLC	added	25.97	248	916	-%
Apr 05, 2024	CWM, LLC	added	6.82	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-81.62	-13,037	6,012	-%
Mar 11, 2024	VANGUARD GROUP INC	added	8.59	4,271,090	9,213,480	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	355,910	355,910	-%

Are Funds Buying or Selling THRD?

Are funds buying THRD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own THRD

No. of Funds

THRD Alerts

1 major insider sales recently.

Unveiling Third Harmonic Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	7.9%	3,182,444	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0%	0	SC 13G/A
Nov 27, 2023	ra capital management, l.p.	5%	2,033,056	SC 13G

Recent SEC filings of Third Harmonic Bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	ARS	ARS
Apr 15, 2024	4	Insider Trading
Apr 11, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 08, 2024	4	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	4	Insider Trading

Peers (Alternatives to Third Harmonic Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Third Harmonic Bio Inc News

Latest updates

Third Harmonic Bio Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet							(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Assets	-1.6%	278	282	286	291	299	305	129
Current Assets	-1.5%	272	277	280	286	293	304	129
Cash Equivalents	-1.8%	269	274	278	282	289	300	128
Net PPE	-6.6%	0.00	0.00	0.00	0.00	0.00	-	-
Liabilities	-7.2%	9.00	9.00	8.00	9.00	10.00	6.00	6.00
Current Liabilities	-8.0%	5.00	6.00	4.00	5.00	6.00	6.00	6.00
Shareholder's Equity	-1.4%	269	273	278	283	289	298	-46.71
Retained Earnings	-6.4%	-114	-107	-100	-92.50	-83.40	-71.90	-48.24
Additional Paid-In Capital	0.8%	383	380	378	375	372	370	2.00
Shares Outstanding	0.9%	40.00	40.00	40.00	39.00	39.00	9.00	4.00
Float	-	-	-	86.00	-	-	388	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-34.0%	-5,607	-4,183	-3,960	-6,675	-9,287	-10,778	-6,739	-8,113	-	-
Share Based Compensation	-23.2%	1,759	2,291	2,845	2,682	2,133	1,009	1,159	450	-	-
Cashflow From Investing	-Infinity%	-1.00	-	-168	-	-36.00	-	-	-	-	-
Cashflow From Financing	1500.0%	798	-57.00	58.00	-	-875	197,563	-697	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

THRD Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 23,964	$ 24,407
General and administrative	19,990	13,301
Total operating expenses	43,954	37,708
Loss from operations	43,954	37,708
Other income, net:
Interest income	(13,108)	(2,555)
Other (income) expense	(22)	2
Total other (income) expense, net	(13,130)	(2,553)
Net loss	$ 30,824	$ 35,155
Net loss per share of common stock, basic	$ 0.78	$ 2.45
Net loss per share of common stock, diluted	$ 0.78	$ 2.45
Weighted-average common stock outstanding, basic	39,645,392	14,353,102
Weighted-average common stock outstanding, diluted	39,645,392	14,353,102

THRD Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 269,070,000	$ 288,877,000
Prepaid expenses and other current assets	3,376,000	3,958,000
Total current assets	272,446,000	292,835,000
Restricted cash	453,000	441,000
Property and equipment, net	169,000	35,000
Right of use asset	3,763,000	4,327,000
Other assets, noncurrent	880,000	1,037,000
Total assets	277,711,000	298,675,000
Current liabilities:
Accounts payable	1,838,000	2,087,000
Accrued Expense And Other Current Liabilities	2,835,000	3,181,000
Operating lease liability, current	745,000	385,000
Total current liabilities	5,418,000	5,653,000
Operating lease liability, noncurrent	3,208,000	3,954,000
Total liabilities	8,626,000	9,607,000
Commitments and contingencies (Note 12)
Stockholders’ deficit:
Common stock, $0.0001 par value, 500,000,000 shares authorized at December 31, 2022 and December 31, 2023; 39,377,222 and 40,104,937 shares issued and outstanding at December 31, 2022 and December 31, 2023, respectively	4,000	4,000
Additional paid-in capital	383,301,000	372,460,000
Accumulated deficit	(114,220,000)	(83,396,000)
Total stockholders' equity	269,085,000	289,068,000
Total liabilities and stockholders' equity	$ 277,711,000	$ 298,675,000

About Third Harmonic Bio Inc

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Natalie C. Holles
WEBSITE	thirdharmonicbio.com
INDUSTRY	Biotechnology
EMPLOYEES	31

Third Harmonic Bio Inc Frequently Asked Questions

What is the ticker symbol for Third Harmonic Bio Inc? What does THRD stand for in stocks?

THRD is the stock ticker symbol of Third Harmonic Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Third Harmonic Bio Inc (THRD)?

As of Mon Apr 29 2024, market cap of Third Harmonic Bio Inc is 453.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of THRD stock?

You can check THRD's fair value in chart for subscribers.

What is the fair value of THRD stock?

You can check THRD's fair value in chart for subscribers. The fair value of Third Harmonic Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Third Harmonic Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for THRD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Third Harmonic Bio Inc a good stock to buy?

The fair value guage provides a quick view whether THRD is over valued or under valued. Whether Third Harmonic Bio Inc is cheap or expensive depends on the assumptions which impact Third Harmonic Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THRD.